Washington Post -- A subsidiary of Abbott Laboratories has agreed to pay more than $41 million to settle allegations that it paid illegal kickbacks to get doctors, physician groups and managed care organizations to prescribe or recommend two of the company’s drugs, Advicor and Niaspan. The Justice Department said Tuesday that Delaware-based Kos Pharmaceuticals also promoted the sale of Advicor for purposes not approved by the Food and Drug Administration. Advicor is for the treatment of cholesterol. Niaspan improves cholesterol levels.
